Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

Treated first FTD-GRN patient with Dose 2 PBFT02 and enrolled second patient; several additional patients being evaluated for trial eligibility

Announced presentation of process development data of a high productivity, suspension-based manufacturing process for PBFT02 at American Society of Gene and Cell Therapy (ASGCT) 28^th Annual Meeting

Read more at globenewswire.com